Dr. Val Adams
Dr. Val Adams

Associate Professor

Dr. Adams is on the graduate faculty of the College of Pharmacy and is a member of the Lucille Parker Markey Cancer Center, where he has a clinical practice site. As director of the hematology/oncology residency program, he has trained four residents and maintains an active research lab. Dr. Adams received his bachelor of science degree in pharmacy from the University of Utah and doctor of pharmacy degree from the University of Texas at Austin jointly with the University of Texas Health Science Center at San Antonio. He completed a residency in hematology/oncology at the Audie L. Murphy Memorial V.A. Hospital in San Antonio, Texas. He then completed a two-year fellowship in immunology and transplantation at the University of Florida. Following the completion of the fellowship, he joined the University of Kentucky faculty in 1996. Research interests: topoisomerase I inhibitors and topoisomerase expression, chemotherapy-induced toxicity, and supportive care issues, including pain control and nutritional effects on chemotherapy outcomes.

Recent Publications

  • Flannery Alexander H, Adams Val R., Burgess David. (2014). Optimizing Postgraduate Year 3 Training. American Journal of Health-System Pharmacy, 71(22), 1924-5.
  • Piascik Mary M., Adams Val R. (2013). Dispensing Biotechnology Products:Handling, Professional Education and Product Information. Chapter 9.
  • Adams Val R., DeRemer David L, Holdsworth Mark T. (2013). Guide to Cancer Therapeutic Regimens. McMahon Publishing,
  • Adams Val R., Balko J. (2013). Lung Cancer. McGraw-Hill, Chapter 90.
  • DeFrates S R, McDonagh Kevin Thomas, Adams Val R. (2013). The Reversal of Inhibitors in Congenital Hemophilia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy/Wiley, 33(2), 157-64.
  • Adams Val R., DeRemer David L, Holdsworth Mark T. (2012). Guide to Cancer Therapeutic Regimens. McMahon Publishing,
  • Adams Val R., Blechner Michael David, Sutphin Stephanie, Lawson Amber P, Steinke Douglas, Wirth Scott M. (2012). Predictors for Severe Tumor Lysis Syndromes. Jounal of Hematology Oncology Pharmacy, 2(2), http://www.jhoponline.com/jhop-issue-archive/2012-issues/june-vol-2-no-2
  • Steinke Douglas, Talbert Jeffery C., Adams Val R., Hitron A. (2012). The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiology/ Elsevier Inc. , 36(4), e243-e250. http://www.cancerepidemiology.net/article/S1877-7821(12)00018-5/abstract
  • Mandock Katherine, Soefje Scott A, Adams Val R. (2011). Bevacizumab in Metastatic Breast Cancer: Ready for Prime Time?. Journal of Hematology Oncology Pharmacy/Green Hill Healthcare Communications, LLC, 1(4), 6-11.
  • Adams Val R., Iacovelli Lew, Sutphin Stephanie, Muluneh Benyam, Bottiglieri Sal. (2011). Blood pressure control in patients receiving bevacizumab in an outpatient cancer center. Journal of Onocology Pharmacy Practice/SAGE Publications, 17(4), 333-338. http://intl-opp.sagepub.com/content/17/4/333